Evidence map›Paper›PMID 20492837›Full record

Trial reportThe Journal of clinical psychiatry2010

Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial.

Theresa M Winhusen, Eugene C Somoza, Gregory S Brigham, David S Liu, Carla A Green, Lirio S Covey, Ivana T Croghan, Lenard A Adler, Roger D Weiss, Jeffrey D Leimberger and 2 more

Registry-linked trialOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical psychiatry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00253747 (A Pilot Study of Osmotic-Release Methylphenidate in Initiating and Maintaining Abstinence in Smokers With ADHD), which is not on this map. Cited by 58 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 8 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00253747 phase3completednot on this map

A Pilot Study of Osmotic-Release Methylphenidate in Initiating and Maintaining Abstinence in Smokers With ADHD

TypeinterventionalSponsorUniversity of CincinnatiRan2005 to 2008Enrolled255ConditionsADHD, SmokingArmsOsmotic-Release Methylphenidate, Placebo
3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 8 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Effect of amphetamines on blood pressure.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Osmotic release oral system methylphenidate prevents weight gain during a smoking-cessation attempt in adults with ADHD.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2013
    Trial
  18. Trial
  19. Trial
  20. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Theresa M WinhusenDepartment of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45220, USA. winhusen@carc.uc.edu
Eugene C Somoza
Gregory S Brigham
David S Liu
Carla A Green
Lirio S Covey
Ivana T Croghan
Lenard A Adler
Roger D Weiss
Jeffrey D Leimberger
Daniel F Lewis
Emily M Dorer
University of Cincinnati · USColumbia University · USDuke University · USHarvard University Press · USKaiser Permanente · USNational Institutes of Health · USUniversity of Cincinnati Medical Center · US

Funding

CU PARTNERS: NY/LONG ISLAND REGIONAL NODEU10DA013035 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI NUNES, EDWARD V., ROTROSEN, JOHN P · 2001 to 2015
$47.6M
Clinical Trials Network, Ohio Valley Node U10DA013732U10DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI WINHUSEN, T JOHN · 2000 to 2015
$45.0M
The National Drug Abuse Treatment Clinical Trials Network (U10)U10DA015831 · NIDA · MC LEAN HOSPITAL (BELMONT, MA) · PI CARROLL, KATHLEEN M., WEISS, ROGER D. · 2002 to 2015
$28.8M
NIDA CLINICAL TRIALS NETWORK - NYC EAST SIDE NODEU10DA013046 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ROTROSEN, JOHN P · 2000 to 2009
$20.2M
OREGON NODE - NATIONAL CLINICAL TRIALS NETWORKU10DA013036 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI MCCARTY, DENNIS · 1999 to 2010
$18.5M
Mentoring in Drug Abuse and Dual Diagnosis ResearchK24DA022288 · NIDA · MCLEAN HOSPITAL · PI WEISS, ROGER D. · 2007 to 2016
$1.8M
NIDA NIH HHS K24 DA022288NIDA NIH HHS U10 DA013035NIDA NIH HHS U10-DA013035NIDA NIH HHS U10 DA013036NIDA NIH HHS U10-DA013036NIDA NIH HHS U10 DA013046NIDA NIH HHS U10-DA013046NIDA NIH HHS U10 DA013732NIDA NIH HHS U10-DA013732NIDA NIH HHS U10 DA015831NIDA NIH HHS U10-DA015831
6 · The paper itself

Abstract

objectiveHigh smoking rates in adults with attention-deficit/hyperactivity disorder (ADHD) and nicotine's amelioration of ADHD suggest that effective ADHD treatment might facilitate abstinence in smokers with ADHD. The present study evaluated if using osmotic-release oral system methylphenidate (OROS-MPH) to treat ADHD enhances response to smoking cessation treatment in smokers with ADHD.

methodA randomized, double-blind, placebo-controlled, 11-week trial with a 1-month follow-up was conducted at 6 clinical sites between December 2005 and January 2008. Adults (aged 18-55 years) meeting DSM-IV criteria for ADHD and interested in quitting smoking were randomly assigned to OROS-MPH titrated to 72 mg/d (n = 127) or placebo (n = 128). All participants received brief weekly individual smoking cessation counseling for 11 weeks and 21 mg/d nicotine patches starting on the smoking quit day (day 27) through study week 11. Outcome measures included prolonged smoking abstinence and DSM-IV ADHD Rating Scale (ADHD-RS) score.

resultsOf 255 randomly assigned participants, 204 (80%) completed the trial. Prolonged abstinence rates, 43.3% and 42.2%, for the OROS-MPH and placebo groups, respectively, did not differ significantly (OR = 1.1; 95% CI, 0.63-1.79; P = .81). Relative to placebo, OROS-MPH evidenced a greater reduction in DSM-IV ADHD-RS score (P < .0001) and in cigarettes per day during the post-quit phase (P = .016). Relative to placebo, OROS-MPH increased blood pressure and heart rate to a statistically, but not clinically, significant degree (P < .05); medication discontinuation did not differ significantly between treatments.

conclusionsTreatment for ADHD did not improve smoking cessation success; OROS-MPH, relative to placebo, effectively treated ADHD and was safe and generally well tolerated in this healthy sample of adult ADHD smokers.

trial registrationclinical trials.gov Identifier: NCT00253747.

Indexed as

Administration, OralAdultAttention Deficit Disorder with HyperactivityCentral Nervous System StimulantsCombined Modality TherapyCounselingDelayed-Action PreparationsDiagnostic and Statistical Manual of Mental DisordersDose-Response Relationship, DrugDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleMethylphenidateMiddle AgedCentral Nervous System StimulantsDelayed-Action PreparationsMethylphenidateNicotine

Identifiers

PMID20492837
PMCPMC3151610
OpenAlexW2015686738

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.